A 28-year-old woman with lepromatous leprosy is started on multidrug therapy. During the 3rd month of treatment, she develops fever, painful nodules, and worsening of skin lesions. Which investigation would best help differentiate between lepra reaction type 2 (Erythema Nodosum Leprosum) and drug toxicity?

Explanation

## Investigation to Differentiate ENL (Lepra Reaction Type 2) from Drug Toxicity ### Clinical Context **Key Point:** When a lepromatous leprosy patient on MDT develops fever, painful nodules, and worsening skin lesions at 3 months, the two main differentials are Erythema Nodosum Leprosum (ENL / Type 2 lepra reaction) and drug toxicity. The **best single investigation** to definitively differentiate these is **skin biopsy with histopathology and immunohistochemistry**. ### Why Skin Biopsy Is the Gold Standard Skin biopsy provides **direct tissue-level evidence** of the pathological process: | Histological Feature | ENL (Type 2 Reaction) | Drug Toxicity | |---|---|---| | **Inflammatory infiltrate** | Dense **neutrophilic** infiltrate in dermis | Eosinophilic infiltrate or toxic epidermal changes | | **Immune complex deposition** | IgG, IgM, C3 deposits on IHC | Absent | | **Granuloma pattern** | Foamy macrophages + neutrophils | No leprosy-specific granuloma | | **Vascular changes** | Leukocytoclastic vasculitis | Toxic/necrotic changes | | **Bacilli** | Abundant AFB (LL pattern) | Unchanged | **Immunohistochemistry (IHC)** can directly demonstrate immune complex (IgG/IgM/C3) deposition in vessel walls and dermis — a hallmark of ENL's Type III hypersensitivity mechanism — which is absent in drug toxicity. ### Why Other Options Are Less Definitive - **Option A (Slit-skin smear / Bacillary Index):** Bacillary index does NOT change acutely in ENL or drug toxicity; unhelpful for differentiation. - **Option C (Serum C3, C4 and CIC):** While ENL is immune complex–mediated and CIC may be elevated with complement consumption, these findings are **non-specific** (seen in other immune complex diseases), not universally present in all ENL episodes, and cannot rule out concurrent drug toxicity. They are supportive, not diagnostic. - **Option D (LFT and RFT):** Useful to detect dapsone/rifampicin organ toxicity but cannot confirm ENL; a patient can have both abnormal LFTs and ENL simultaneously. ### Pathophysiology of ENL (for context) ENL is a **Type III hypersensitivity** (immune complex–mediated) reaction occurring in LL/BL patients with high antigen load. Antigen–antibody complexes deposit in tissues, activate complement, and recruit neutrophils — all of which are directly visualized on biopsy. However, the **tissue diagnosis** is definitive because it simultaneously rules in ENL and rules out drug-induced toxic dermatitis. **Clinical Pearl:** Skin biopsy is the investigation of choice when a definitive single test is needed to distinguish ENL from drug toxicity, as it provides pathognomonic histological findings (neutrophilic infiltrate + immune complex deposition on IHC) not replicated by any serum marker alone. [cite: Harrison's Principles of Internal Medicine 21e Ch 187; Robbins & Cotran Pathologic Basis of Disease 10e; KD Tripathi Essentials of Medical Pharmacology 8e Ch 50]